Ronny Kalash
Radiation Oncology · Sherman Oaks, CANPI 1811317175
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,985 of the $7,652 with a category attached, or 78.2%. AstraZeneca accounts for 81.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $3,566 and has fallen 99.4% since, to $22 in 2025.
Across 36 payments — averaging $212.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Sanofi$375
- Daiichi Sankyo Inc.$360
- West Therapeutics Development, LLC$101
- Novocure Inc.$92
- Blue Earth Diagnostics$77
- plus $403 from 12 others
What the payments were for
- Consulting fees$5,98578%
- Speaking & faculty fees$73510%
- Travel & lodging$2113%
- Food & beverage$7219%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $6,245 |
| Sanofi | 1 | $375 |
| Daiichi Sankyo Inc. | 1 | $360 |
| West Therapeutics Development, LLC | 6 | $101 |
| Novocure Inc. | 5 | $92 |
| Blue Earth Diagnostics | 3 | $77 |
| GE HealthCare | 2 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Teleflex LLC | 1 | $42 |
| Myriad Genetic Laboratories, Inc. | 2 | $37 |
| Tactile Systems Technology Inc | 2 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $34 |
| Boston Scientific | 1 | $33 |
| Bayer | 1 | $32 |
| Myovant Sciences Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Siemens Medical Solutions USA, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$3,150
- TAGRISSO$3,046
- NO PRODUCT DISCUSSED$375
How this compares
$7,652 in reported general payments places this provider in the 85th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 48 | $323 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $228 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Sherman Oaks
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
- Rizwan NuraniApple Valley$220K
- Drew MoghanakiLos Angeles$183K
- Jyoti MayadevSan Diego$170K
- Percy LeeIrvine$125K
- Felix FengSan Francisco$99K
- Hyun KimDuarte$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.